Over the last nine years OrbiMed has gathered more than a half billion dollars earmarked for its Asia group’s life sciences investments. And now it’s doubling down, shooting for a record $450 million fund that could easily take the total above $1 billion.
OrbiMed Asia disclosed its interest in the new fund in a filing with the SEC, a little more than two years after grabbing $325 million for its second fund. Recent investments include CBT Pharmaceuticals, led by CEO Sanjeev Redkar, which is working on checkpoint inhibitors. OrbiMed also participated in the $100 million round for Shanghai-based Zai Lab early last year. Earlier rounds supported Shasun — merged into Strides Shasun — and Mumbai-based Bharat Serums.
Partners at OrbiMed have been steadily upping their game in the Asia market as they gain experience. And they have expressed an interest in a spectrum of investments, running from drug development to medtech and enabling technologies. China, which has a burgeoning biotech industry, has attracted considerable attention as well.
Don’t be surprised if the venture player shoots for more than $450 million at the close. Topping up these funds is all the rage these days as institutional investors weigh in with established players.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription